B
Bitterroot Bio
Biotech & Life Sciences · Palo Alto, United States · Founded 2021
Innovative immunotherapies targeting the root causes of cardiovascular disease through advanced cardio immunology research MoreLess
Bitterroot Bio, operating under the domain brbio.com, is a pioneering startup in the healthcare sector, specifically focusing on the emerging field of cardio-immunology. The company is dedicated to developing innovative immunotherapies to treat cardiovascular diseases. Their primary market is patients suffering from cardiovascular conditions, particularly those related to inflammation and immune response, such as atherosclerosis.
The company's business model revolves around harnessing the power of immunotherapy, a treatment that uses the body's natural defenses to fight diseases. Bitterroot Bio's approach is unique as it targets the root causes of cardiovascular diseases rather than just treating the symptoms. This is achieved by understanding the role of immune cells and immune modulators in the development and progression of these diseases.
Bitterroot Bio generates revenue by developing and delivering these innovative therapies. The company collaborates closely with cardiologists to ensure the safety and efficacy of their treatments, thereby providing a new hope for patients suffering from cardiovascular diseases.
In simple terms, Bitterroot Bio is working on treatments that can help the body's immune system fight off heart diseases. One of their main focuses is atherosclerosis, a disease where fatty deposits build up in the arteries, making it hard for blood to flow. They believe this disease is caused by inflammation and are developing treatments to stop this inflammation.
Keywords: Cardiovascular Diseases, Immunotherapy, Cardio-Immunology, Atherosclerosis, Inflammation, Innovative Therapies, Immune System, Healthcare, Biotechnology, Treatment Development.
Company overview
Bitterroot Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- Palo Alto, United States
- Employees
- 30
- Open positions
- None listed
- Dealroom signal
- 25.7
Valuation & funding
Bitterroot Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2023 | $145M | $580M | Koch Disruptive Technologies · ARCH Venture Partners · GV · Alexandria Venture Investments | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | Stanford University | — |
Growth signals
Bitterroot Bio website traffic
Latest recorded traffic for Bitterroot Bio is 2.9K monthly website visits, down 12.1% over the last three months. Bitterroot Bio's team declined 14.3% over the past year.
Comparisons
Bitterroot Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Bitterroot Bio's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Bitterroot Bio has talent and traffic
team presence
In the news
Latest news about Bitterroot Bio
Recent press, funding announcements, and product moves mentioning Bitterroot Bio — open to read from the original sources.
Market sentiment
What the market is saying about Bitterroot Bio
An AI-synthesized read of the highest-engagement posts about Bitterroot Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bitterroot Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.